Effects of miR-145-5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways

miR-542-3p suppresses invasion and metastasis by targeting the proto-oncogene serine/threonine protein kinase, PIM1, in melanoma

(2016) Zhen Rang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling

(2016) Jasmina Paluncic et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma

(2016) Hamed Mirzaei et al.   EUROPEAN JOURNAL OF CANCER

Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer

(2016) Francesco Pappalardo et al.   PLoS One

Inhibition of SW620 human colon cancer cells by upregulating miRNA-145

(2016) Chen Li et al.   WORLD JOURNAL OF GASTROENTEROLOGY

miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α

(2015) Jianda Zhou et al.   CANCER BIOLOGY & THERAPY

Targeting drivers of melanoma with synthetic small molecules and phytochemicals

(2015) Leah Ray Strickland et al.   CANCER LETTERS

miR-21 and miR-145 cooperation in regulation of colon cancer stem cells

(2015) Yingjie Yu et al.   Molecular Cancer

MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in malignant melanoma

(2015) Liron Zehavi et al.   Molecular Cancer

Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence

(2015) Ulrike Schick et al.   RADIOTHERAPY AND ONCOLOGY

Molecular drivers of cellular metabolic reprogramming in melanoma

(2015) Cecilie Abildgaard et al.   TRENDS IN MOLECULAR MEDICINE

MicroRNA-145 inhibits growth and migration of breast cancer cells through targeting oncoprotein ROCK1

(2015) Meizhu Zheng et al.   TUMOR BIOLOGY

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer

(2015) Igor Vujic et al.   Oncotarget

miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2

(2015) Szu-Mam Liu et al.   Oncotarget

Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia

(2014) D. B. Johnson et al.   CLINICAL CANCER RESEARCH

NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract—A study of 24 cases from the Netherlands

(2014) Adriana C.H. van Engen-van Grunsven et al.   GYNECOLOGIC ONCOLOGY

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

(2014) Deborah JL Wong et al.   Molecular Cancer

Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions

(2013) Marta Batus et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Emerging insights into resistance to BRAF inhibitors in melanoma

(2013) Amanda D. Bucheit et al.   BIOCHEMICAL PHARMACOLOGY

MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6

(2013) Yuan Shao et al.   Cancer Cell International

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

(2013) Carolyn D. Britten   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Characteristics of Lung Cancers Harboring NRAS Mutations

(2013) K. Ohashi et al.   CLINICAL CANCER RESEARCH

Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line

(2013) Wei Peng et al.   TUMOR BIOLOGY

Melanoma as a model tumour for immuno-oncology

(2012) M. Maio   ANNALS OF ONCOLOGY

MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF

(2012) Chao Zou et al.   CELL CYCLE

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

NRAS mutant melanoma: biological behavior and future strategies for therapeutic management

(2012) I V Fedorenko et al.   ONCOGENE

The molecular mechanism of microRNA-145 to suppress invasion–metastasis cascade in gastric cancer

(2012) P Gao et al.   ONCOGENE

A Functional Screen Identifies Specific MicroRNAs Capable of Inhibiting Human Melanoma Cell Viability

(2012) Jos B. Poell et al.   PLoS One

NRAS mutation status is an independent prognostic factor in metastatic melanoma

(2011) John A. Jakob et al.   CANCER

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative Study of Anti-Oncogenic MicroRNA-145 in Canine and Human Malignant Melanoma

(2011) Shunsuke NOGUCHI et al.   JOURNAL OF VETERINARY MEDICAL SCIENCE

The miRNA expression profile of the uveal melanoma

(2011) ChengHsun Yang et al.   Science China-Life Sciences

Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway

(2010) O. A. Kent et al.   GENES & DEVELOPMENT

Real-time monitoring of cell transplantation in mouse dystrophic muscles by a secreted alkaline phosphatase reporter gene

(2009) X Gerard et al.   GENE THERAPY